Pennsylvania says GSK to invest over $800 million in biopharma hub, create 300 jobs

• The expansion will create over 300 new jobs and retain approximately 4,500 existing full-time positions in Pennsylvania
• The new hub will include commercial-scale biologics manufacturing, a research pilot plant, and a centralized quality-control laboratory combining production, R&D, and digital operations
• GSK will be eligible for state manufacturing tax incentives, with the project representing nearly $1.7 billion in total Pennsylvania investment when combined with the Lancaster County facility

GSK to Invest $800M+ in Pennsylvania Biopharma Hub, Creating 300 Jobs

GSK announced plans to invest over $800 million to transform its Upper Merion, Pennsylvania site into a comprehensive biopharmaceutical manufacturing and research hub, according to Pennsylvania Governor Josh Shapiro's office on Friday.

Key Investment Details:

• Total investment: Over $800 million
• Location: Upper Merion, Montgomery County, Pennsylvania
• Timeline: Construction planned to begin in 2027
• New jobs: More than 300 over the next five years
• Existing jobs retained: Approximately 4,500 full-time positions

Facility Components:

The expanded site will integrate multiple operations including drug manufacturing, research and development, quality testing, and digital operations. Specific additions include a new commercial-scale biologics manufacturing facility, a research pilot plant, and a centralized quality-control laboratory.

Production Focus:

The facility will support both clinical and commercial production of biologic medicines, aimed at accelerating the development and supply of future treatments.

Broader Pennsylvania Investment:

Combined with GSK's previously announced Lancaster County facility project, the company's total planned investment in Pennsylvania approaches $1.7 billion. GSK's U.S. headquarters is located in Philadelphia.

Financial Incentives:

Pennsylvania officials confirmed GSK will be eligible for state manufacturing tax incentives tied to this investment.

Market Implications:

This significant capital commitment demonstrates GSK's focus on expanding its biologics manufacturing capacity in the U.S., positioning the company to meet growing demand for biopharmaceutical products while strengthening its domestic production capabilities and research infrastructure.